ArticleInfectious diseases of poverty2018
Pharmacological and immunological effects of praziquantel against Schistosoma japonicum: a scoping review of experimental studies.
Article in Infectious diseases of poverty, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 88 citations in OpenAlex.
- T cell responses in repeated controlled human schistosome infection compared to natural exposure.Nature communications · 2025Trial
- Article
- N- and O‑Prenylated Quinolones: Syntheses andACS medicinal chemistry letters · 2026Article
- Discovery and biological evaluation of novelMicrobiology spectrum · 2026Article
- Crystal structure of Schistosoma mansoni cathepsin D1 in complex with a nanobody reveals the conformation of the propeptide-bound state.Acta crystallographica. Section D, Structural biology · 2026Article
- Prevalence and associated factors of schistosomiasis among children and adolescents visiting Chitokoloki Mission Hospital of Zambezi District.BMC infectious diseases · 2025Article
- Computational and experimental exploration of statin and statin-like compounds as potential treatment of schistosomiasis.PLoS neglected tropical diseases · 2025Article
- Structural Mechanisms Driving the Selective Efficacy of Oxamniquine against Schistosoma mansoni and Schistosoma japonicum.Cell biochemistry and biophysics · 2025Article
- Evaluation of metformin's effect on the adult and juvenile stages ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Article
- Mass spectrometry imaging reveals spatial metabolic variation and the crucial role of uridine metabolism in liver injury caused by Schistosoma japonicum.PLoS neglected tropical diseases · 2025Article
- Efficacy of Praziquantel in TreatingBiomedicines · 2024Article
- Review
- Mechanochemical Synthesis of New Praziquantel Cocrystals: Solid-State Characterization and Solubility.Crystal growth & design · 2024Article
- Inhibiting Liver Autophagy and Promoting Hepatocyte Apoptosis byTropical medicine and infectious disease · 2024Article
- Targeting SmCB1: Perspectives and Insights to Design Antischistosomal Drugs.Current medicinal chemistry · 2024Review
- Article
- Mining host candidate regulators of schistosomiasis-induced liver fibrosis in response to artesunate therapy through transcriptomics approach.PLoS neglected tropical diseases · 2023Article
- Evolution of tetraspanin antigens in the zoonotic Asian blood fluke Schistosoma japonicum.Parasites & vectors · 2023Article
- Unexpected rapid symptom response after praziquantel to intestinalSAGE open medical case reports · 2023Article
- In vivo efficiency of praziquantel treatment of single-sex Schistosoma japonicum aged three months old in mice.International journal for parasitology. Drugs and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy for schistosomiasis has been around for 100 years. During the past century, great efforts have been made to develop new antischistosomal drugs from antimonials to nonantimonials, and some of these have been used extensively in clinical treatment. With the exception of a few drugs, such as oxamniquine and metrifonate, most of the antischistosomals developed in the pre-praziquantel period have variable limitations with respect to safety and efficacy. Although oxamniquine and metrifonate have been used for schistosomiasis control, they are only effective against Schistosoma mansoni and S. haematobium, respectively. Currently, praziquantel is the only drug used for treatment of all five species of human schistosomes. In this review, the pharmacological and immunological effects of praziquantel against S. japonicum are summarized and discussed. MAIN TEXT: From the end of the 1970s until the 2000s, scientists have conducted a series of experimental studies on the effects of praziquantel against S. japonicum. These have included examining its unique pharmacological action on schistosomes, the characteristics in susceptibility of the different developmental stages of schistosomes to the drug, the relationship between plasma concentration of the drug and efficacy, the impact of host factors on cidal action of the drug, prevention and early treatment of schistosomal infection, as well as praziquantel-resistant schistosomiasis.
conclusionThe effects of praziquantel against S. japonicum, as elucidated by the experimental studies that are reviewed in this paper, may have some reference significance for the development of new antischistosomals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.